Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.

Investigational new drugs - 1 Oct 2020

Li Tao, Jia Dong-Dong, Teng Li-Song

Abstract excerpt

Background Pembrolizumab has robust antitumor activity in advanced melanoma and has been approved for the treatment of melanoma in many countries. Adjuvant pembrolizumab was associated with longer recurrence-free survival (RFS) in patients with resected stage III melanoma. We herein report on the RFS outcomes of Chinese patients with resected stage III melanoma receiving adjuvant pembrolizumab in comparison to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to B7-H1 Antigen

Share to Disease-Free Survival

Share to Infusions, Intravenous

Share to Interferon alpha-2

Share to Microsatellite Instability

Source

Identifiers

PMID: 32072356
DOI: 10.1007/s10637-020-00913-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.PMID 32072356Read ↗

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.Semantic proximity Read ↗

Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.Semantic proximity Read ↗

A retrospective study of anti-PD-1 combined with temozolomide adjuvant therapy for stage III resected acral melanomaSemantic proximity Read ↗

Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.Semantic proximity Read ↗

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of MelanomaSemantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.Semantic proximity Read ↗

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.